Faeth Therapeutics, Inc. (FTH) vs Lexicon Pharmaceuticals, Inc. (LXRX)
A side-by-side comparison of Faeth Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FTH
Faeth Therapeutics, Inc.
$28.61HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
LXRX
Lexicon Pharmaceuticals, Inc.
$1.75HealthcareDelayed quote: Oct 6, 2026, 12:24 PM EDT
Total return — FTH vs LXRX
growth of $100 · dividends reinvested · last 6yFTH -92.8% (-35.5%/yr)LXRX -79.0% (-22.9%/yr)LXRX compounded faster over this window
FTH LXRX
FTH vs LXRX: by the numbers
- •LXRX is the larger company ($775M vs $737M market cap).
- •Both run net losses; FTH's is the smaller (0.00% vs -147.38% net margin).
Metrics side by side
Valuation
| Metric | FTH | LXRX |
|---|---|---|
| P/S ratio | N/A | 18.69 |
| P/B ratio | 4.26 | 4.44 |
Profitability
| Metric | FTH | LXRX |
|---|---|---|
| Gross margin | 0.00% | 98.85% |
| Operating margin | 0.00% | -98.21% |
| Net margin | 0.00% | -147.38% |
| ROE | -113.05% | -35.02% |
| ROIC | -110.62% | -23.16% |
Growth (annualized)
| Metric | FTH | LXRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 42.36% |
| Total return CAGR (5Y) | -31.75% | -18.54% |
Frequently asked
- How have FTH and LXRX total returns compared?
- Over the past 5 years, FTH delivered -31.75% and LXRX delivered -18.54% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Faeth Therapeutics ROELexicon Pharmaceuticals ROEFaeth Therapeutics operating marginLexicon Pharmaceuticals operating marginFaeth Therapeutics revenue growthLexicon Pharmaceuticals revenue growthFaeth Therapeutics free cash flowLexicon Pharmaceuticals free cash flow
Faeth Therapeutics & Lexicon Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.